Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib vs Chemotherapy in Neoadjuvant EGFR-mutant NSCLC
NCT03656393Phase 3Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Aug 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: 2-year Disease-Free Survival. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03656393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656393.